Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
AstraZeneca Japan Taps Ex-Takeda Japan Oncology Head as New Chief
Former Takeda Pharmaceutical exec Takafumi Horii was appointed on July 1 as president of the Japan unit of AstraZeneca. He took over the reins from its outgoing president Stefan Woxström, who stepped down from his role on the same day…
To read the full story
Related Article
BUSINESS
- Rakuten to Launch Japan PI of RM-0256 Photoimmunotherapy in April-June
February 17, 2026
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
- Ono’s Velexbru Accepted for FDA Review in PCNSL
February 17, 2026
- Celltrion Sets April 28 Launch Date for Japan’s 1st Actemra Biosimilar
February 17, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…